Chronic myelomonocytic leukemia with double-mutations in DNMT3A and FLT3-ITD treated with decitabine and sorafenib

References

• Padron E, Komrokji R, List AF. The clinical management of chronic myelomonocytic leukemia. Clin Adv Hematol Oncol 2014; 12:172-178. PMID:24927265.
   PubMedGoogle Scholar
• Sherdlow SH, Campo E, Harris NL. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. IARC; Lyon: 2008, 4th edition:76.
   Google Scholar
• Padron E, Garcia-Manero G, Patnaik MM, Itzykson R, Lasho T, Nazha A, Rampal RK, Sanchez ME, Jabbour E, Al Ali NH, et al. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J 2015; 5:e333; PMID:26230957; https://doi.org/10.1038/bcj.2015.53
   PubMed Web of Science ®Google Scholar
• Zoi K, Cross NC. Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable. Int J Hematol 2015; 101:229-42; PMID:25212680; https://doi.org/10.1007/s12185-014-1670-3
   PubMed Web of Science ®Google Scholar
• Padron E, Komrokji R, List AF. The clinical management of chronic myelomonocytic leukemia. Clin Adv Hematol Oncol 2014; 12:172-8. PMID:24927265
   PubMedGoogle Scholar
• Xu Y, McKenna RW, Karandikar NJ, Pildain AJ, Kroft SH. Flow cytometric analysis of monocytes as a tool for distinguishing chronic myelomonocytic leukemia from reactive monocytosis. Am J Clin Pathol 2005; 124:799-806; PMID:16203279; https://doi.org/10.1309/HRJ1XKTD77J1UTFM
   PubMed Web of Science ®Google Scholar
• Such E, Germing U, Malcovati L, Cervera J, Kuendgen A, Della Porta MG, Nomdedeu B, Arenillas L, Luño E, Xicoy B, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood 2013; 121:3005-15; PMID:23372164; https://doi.org/10.1182/blood-2012-08-452938
   PubMed Web of Science ®Google Scholar
• Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M, Berthon C, Adès L, Fenaux P, Beyne-Rauzy O, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013; 31:2428-36; PMID:23690417; https://doi.org/10.1200/JCO.2012.47.3314
   PubMed Web of Science ®Google Scholar
• Meggendorfer M, Roller A, Haferlach T, Eder C, Dicker F, Grossmann V, Kohlmann A, Alpermann T, Yoshida K, Ogawa S, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML).Blood 2012; 120:3080-8; PMID:22919025; https://doi.org/10.1182/blood-2012-01-404863
   PubMed Web of Science ®Google Scholar
• Hou HA, Kuo YY, Liu CY, Chou WC, Lee MC, Chen CY, Lin LI, Tseng MH, Huang CF, Chiang YC, et al. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood 2012; 119:559-568; PMID:22077061; https://doi.org/10.1182/blood-2011-07-369934
   PubMed Web of Science ®Google Scholar
• Hahn CN, Ross DM, Feng J, Beligaswatte A, Hiwase DK, Parker WT, Ho M, Zawitkowski M, Ambler KL, Cheetham GD, et al. A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone.Leukemia 2015; 9:1-4.; PMID:25748685; https://doi.org/10.1038/leu.2015.67
   Web of Science ®Google Scholar
• Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, Kandoth C, Payton JE, Baty J, Welch J, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363:2424-33; PMID:21067377; https://doi.org/10.1056/NEJMoa1005143
   PubMed Web of Science ®Google Scholar
• Yan XJ, Xu J, Gu ZH, Pan CM, Lu G, Shen Y, Shi JY, Zhu YM, Tang L, Zhang XW, et al. Exome sequencing identifi es somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 2011; 43:309-15; PMID:21399634; https://doi.org/10.1038/ng.788
   PubMed Web of Science ®Google Scholar
• Li Y, Zhu B. Acute myeloid leukemia with DNMT3A mutations. Leuk Lymphoma 2014; 55:2002-12; PMID:24283755; https://doi.org/10.3109/10428194.2013.869802
   PubMed Web of Science ®Google Scholar
• Gale RE, Lamb K, Allen C, El-Sharkawi D, Stowe C, Jenkinson S, Tinsley S, Dickson G, Burnett AK, Hills RK, et al. Simpson's Paradox and the Impact of Different DNMT3A Mutations on Outcome in Younger Adults WithAcute Myeloid Leukemia.J Clin Oncol 2015; 33:2072-83; PMID:25964253; https://doi.org/10.1200/JCO.2014.59.2022
   PubMed Web of Science ®Google Scholar
• Zare-Abdollahi D, Safari S, Movafagh A, Riazi-Isfahani S, Ghadyani M, Feyzollah HG, Nasrollahi MF, Omrani MD. A mutational and expressional analysis of DNMT3A in acute myeloid leukemia cytogenetic subgroups. Hematology 2015; 20:397-404; PMID:25592687; https://doi.org/10.1179/1607845415Y.0000000001
   PubMed Web of Science ®Google Scholar
• Tie R, Zhang T, Fu H, Wang L, Wang Y, He Y, Wang B, Zhu N, Fu S, Lai X, et al. Association between DNMT3A mutations and prognosis of adults with de novo acute myeloid leukemia: a systematic review and meta-analysis. PLoS One 2014; 9:e93353; PMID:24936645; https://doi.org/10.1371/journal.pone.0093353
   PubMed Web of Science ®Google Scholar
• Thol F, Damm F, Lüdeking A, Winschel C, Wagner K, Morgan M, Yun H, Göhring G, Schlegelberger B, Hoelzer D, et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 2011; 29:2889-96; PMID:21670448; https://doi.org/10.1200/JCO.2011.35.4894
   PubMed Web of Science ®Google Scholar
• Ibrahem L, Mahfouz R, Elhelw L, Abdsalam EM, Soliman R. Prognostic significance of DNMT3A mutations in patients with acute myeloid leukemia. Blood Cells Mol Dis 2015; 54:84-9; PMID:25172541; https://doi.org/10.1016/j.bcmd.2014.07.015
   PubMed Web of Science ®Google Scholar
• Shivarov V, Gueorguieva R, Stoimenov A, Tiu R. DNMT3A mutation is a poor prognosis biomarker in AML: results of a meta-analysis of 4500 AML patients. Leuk Res 2013; 37:1445-50; PMID:23962568; https://doi.org/10.1016/j.leukres.2013.07.032
   PubMed Web of Science ®Google Scholar
• Gaidzik VI, Schlenk RF, Paschka P, Stölzle A, Späth D, Kuendgen A, von Lilienfeld-Toal M, Brugger W, Derigs HG, Kremers S, et al. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Blood 2013; 121:4769-77; PMID:23632886; https://doi.org/10.1182/blood-2012-10-461624
   PubMed Web of Science ®Google Scholar
• Jankowska AM, Makishima H, Tiu RV, Szpurka H, Huang Y, Traina F, Visconte V, Sugimoto Y, Prince C, O'Keefe C, et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 2011; 118:3932-41; PMID:21828135; https://doi.org/10.1182/blood-2010-10-311019
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab O, Pardanani A, Rampal R, Lasho TL, Levine RL, Tefferi A. DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia 2011; 25:1219-20; PMID:21519343; https://doi.org/10.1038/leu.2011.82
   PubMed Web of Science ®Google Scholar
• Xu J, Wang YY, Dai YJ, Zhang W, Zhang WN, Xiong SM, Gu ZH, Wang KK, Zeng R, Chen Z, et al. DNMT3A Arg882 mutation drives chronic myelomonocytic leukemia through disturbing gene expression/DNA methylation in hematopoietic cells. Proc Natl Acad Sci U S A 2014; 111:2620-5; PMID:24497509; https://doi.org/10.1073/pnas.1400150111
   PubMed Web of Science ®Google Scholar
• Chang YI, You X, Kong G, Ranheim EA, Wang J, Du J, Liu Y, Zhou Y, Ryu MJ, Zhang J. Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis. Leukemia 2015; 29:1847-56; PMID:25801914; https://doi.org/10.1038/leu.2015.85
   PubMed Web of Science ®Google Scholar
• Kar SA, Jankowska A, Makishima H, Visconte V, Jerez A, Sugimoto Y, Muramatsu H, Traina F, Afable M, Guinta K, et al. Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenilemyelomonocytic leukemia. Haematologica 2013; 98:107-13; PMID:22773603; https://doi.org/10.3324/haematol.2012.064048
   PubMed Web of Science ®Google Scholar
• Stirewalt DL, Radich JP. The role of flt3 in haematopoietic malignancies. Nat Rev Cancer 2003; 3:650-65; PMID:12951584; https://doi.org/10.1038/nrc1169
   PubMed Web of Science ®Google Scholar
• Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, Sonoda Y, Fujimoto T, Misawa S. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996; 10:1911-8. PMID:8946930
   PubMed Web of Science ®Google Scholar
• Port M, Böttcher M, Thol F, Ganser A, Schlenk R, Wasem J, Neumann A, Pouryamout L. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis. Ann Hematol 2014; 93:1279-86; PMID:24801015; https://doi.org/10.1007/s00277-014-2072-6
   PubMed Web of Science ®Google Scholar
• Wang SA, Galili N, Cerny J, Sechman E, Chen SS, Loew J, Liu Q, Fadare O, Hasserjian R, Jones D, et al. Chronic myelomonocytic leukemia evolving from preexisting myelodysplasia shares many features with de novo disease. Am J Clin Pathol 2006; 126:789-97; PMID:17050076; https://doi.org/10.1309/FU04P779U310R3EE
   PubMed Web of Science ®Google Scholar
• Chen W, Huang Q. Detection of FLT3/ITD, JAK2(V617F) and NPM1 gene mutations in chronic myelomonocytic leukemia. Leuk Res 2009; 33:e207-9; PMID:19540590; https://doi.org/10.1016/j.leukres.2009.05.015
   PubMedGoogle Scholar
• Daver N, Strati P, Jabbour E, Kadia T, Luthra R, Wang S, Patel K, Ravandi F, Cortes J, Qin Dong X, Kantarjian H, Garcia-Manero G. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol 2013; 88:56-9; PMID:23115106; https://doi.org/10.1002/ajh.23345
   PubMed Web of Science ®Google Scholar
• Shih LY, Lin TL, Wang PN, Wu JH, Dunn P, Kuo MC, Huang CF. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome. Cancer 2004; 101:989-98; PMID:15329908; https://doi.org/10.1002/cncr.20440
   PubMed Web of Science ®Google Scholar
• Lee BH, Tothova Z, Levine RL, Anderson K, Buza-Vidas N, Cullen DE, McDowell EP, Adelsperger J, Fröhling S, Huntly BJ, Beran M, Jacobsen SE, Gilliland DG. FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. Cancer Cell 2007; 12:367-80; PMID:17936561; https://doi.org/10.1016/j.ccr.2007.08.031
   PubMed Web of Science ®Google Scholar
• Loghavi S, Zuo Z, Ravandi F, Kantarjian HM, Bueso-Ramos C, Zhang L, Singh RR, Patel KP, Medeiros LJ, Stingo F, et al. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3and NPM1 mutations. J Hematol Oncol 2014 Oct 4; 7:74; PMID:25281355; https://doi.org/10.1186/s13045-014-0074-4
   PubMed Web of Science ®Google Scholar
• Aribi A, Borthakur G, Ravandi F, Shan J, Davisson J, Cortes J, Kantarjian H. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer 2007; 109:713-7; PMID:17219444; https://doi.org/10.1002/cncr.22457
   PubMed Web of Science ®Google Scholar
• Wijermans PW, Rüter B, Baer MR, Slack JL, Saba HI, Lübbert M. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res 2008; 32:587-91; PMID:17881052; https://doi.org/10.1016/j.leukres.2007.08.004
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109:52-7; PMID:16882708; https://doi.org/10.1182/blood-2006-05-021162
   PubMed Web of Science ®Google Scholar
• Meldi K, Qin T, Buchi F, Droin N, Sotzen J, Micol JB, Selimoglu-Buet D, Masala E, Allione B, Gioia D, et al. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. J Clin Invest 2015; 125:1857-72; PMID:25822018; https://doi.org/10.1172/JCI78752
   PubMed Web of Science ®Google Scholar
• Deng Q, Li JY, Liu PJ, Zhao MF. Successful management of acute myeloid leukemia transformed from chronic myelomonocytic leukemia in the elderly by a combination regimen of decitabine and cytarabine, aclarubicin and granulocyte colony-stimulating factor: A case report. Oncol Lett 2015; 9:1217-20. PMID:25663885; https://doi.org/10.3892/ol.2015.2870
   PubMed Web of Science ®Google Scholar
• Smith CC, Lin K, Stecula A, Sali A, Shah NP. FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors. Leukemia 2015; 29:2390-2; PMID:26108694; https://doi.org/10.1038/leu.2015.165
   PubMed Web of Science ®Google Scholar
• Tschan-Plessl A, Halter JP, Heim D, Medinger M, Passweg JR, Gerull S. Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation. Ann Hematol 2015; 94:1899-905; PMID:26233683; https://doi.org/10.1007/s00277-015-2461-5
   PubMed Web of Science ®Google Scholar
• Kosmider O, Chapuis N, Kaltenbach S, Coriat R, Boudou Rouquette P, Willems L, Chesnais V, Radford-Weiss I, Bardet V, Mayeux P, et al. Sustained leukemia-free state and molecular response to sorafenib in a patient with chronic myelomonocytic leukemia in transformation driven by homozygous FLT3-ITD malignant hematopoiesis. Clin Lymphoma Myeloma Leuk 2013; 13:347-50; PMID:23246161; https://doi.org/10.1016/j.clml.2012.11.007
   PubMed Web of Science ®Google Scholar
• von Bubnoff N, Rummelt C, Menzel H, Sigl M, Peschel C, Duyster J. Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib. Leukemia 2010; 24:1523-5; PMID:20520641; https://doi.org/10.1038/leu.2010.122
   PubMed Web of Science ®Google Scholar
• Chan SM, Majeti R. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia. Int J Hematol 2013; 98:648-57; PMID:23949914; https://doi.org/10.1007/s12185-013-1407-8
   PubMed Web of Science ®Google Scholar
• Pløen GG, Nederby L, Guldberg P, Hansen M, Ebbesen LH, Jensen UB, Hokland P, Aggerholm A. Persistence of DNMT3A mutations at long-term remission in adult patients with AML. Br J Haematol 2014; 167:478-86; PMID:25371149; https://doi.org/10.1111/bjh.13062
   PubMed Web of Science ®Google Scholar
• Mori Y, Yoshimoto G, Kumano T, Miyamoto T, Iino T, Takenaka K, Iwasaki H, Harada N, Kinukawa N, Nagafuji K, et al. Distinctive expression of myelomonocytic markers and down-regulation of CD34 in acute myelogenous leukaemia with FLT3 tandem duplication and nucleophosmin mutation. Eur J Haematol 2007; 79:17-24; PMID:17598835; https://doi.org/10.1111/j.1600-0609.2007.00866.x
   PubMed Web of Science ®Google Scholar
• Chang E, Ganguly S, Rajkhowa T, Gocke CD, Levis M, Konig H. The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells. Leukemia 2016; 30:1025-32; PMID:26686245; https://doi.org/10.1038/leu.2015.346
   PubMed Web of Science ®Google Scholar